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Abstract 
The frontal lobe has an extended maturation period and may be vulnerable to the long-term 
effects of schizophrenia. We tested this hypothesis by studying the relationship between 
duration of illness (Dol) and grey matter (GM) volume across the whole brain. Sixty-four 
patients with schizophrenia and 25 healthy controls underwent structural MRI scanning and 
neuropsychological assessment. We performed regression analyses in patients to examine the 
relationship between Dol and GM and cerebro-spinal fluid (CSF) volumes across the whole 
brain, and correlations in controls between age and GM or CSF volume of the regions where 
GM or CSF volumes were associated with Dol in patients. Correlations were also performed 
between GM volume in the regions associated with Dol and neuropsychological performance. 
A longer Dol was associated with lower GM volume in the left dorsomedial prefrontal cortex 
(PFC), right middle frontal cortex, left fusiform gyrus (FG) and left cerebellum (lobule III). 
Additionally, age was inversely associated with GM volume in the left dorsomedial PFC in 
patients, and in the left FG and CSF excess near the left cerebellum in healthy controls. 
Greater GM volume in the left dorsomedial PFC was associated with better working memory, 
attention and psychomotor speed in patients. Our findings suggest that the right middle frontal 
cortex is particularly vulnerable to the long-term effect of schizophrenia illness whereas the 
dorsomedial PFC, FG and cerebellum are affected by both a long Dol and aging. The effect of 
illness chronicity on GM volume in the left dorsomedial PFC may be extended to brain structure-
neuropsychological function relationships. 
2 
Pr -Print
1 Introduction 
The prefrontal cortex (PFC) plays a key role in most neuropsychological functions, being 
associated with working memory, problem-solving, decision-making, response inhibition, reward 
and attention [1]. From an evolutionary perspective, it is regarded as a higher-order brain 
structure, forming a part of the neo-cortex [2]. 
In schizophrenia, there is reduced PFC volume compared to healthy populations [3]. 
This characteristic, in addition to an impairment in most frontal lobe-based neuropsychological 
functions, such as verbal fluency, set-shifting, n-back tasks, vigilance and response inhibition 
[4], would suggest that the PFC is important to the psychopathology of schizophrenia [5]. The 
frontal lobe has a maturation period extending into the fifth decade [6]. While some brain 
structural changes are reported early in the course of schizophrenia [7-11], the longer time to 
maturation of the frontal lobe would render it more vulnerable to the emergence and course of 
schizophrenia later in the course of schizophrenia illness. Notably, a post-mortem study of 
schizophrenia patients (n=14, mean age 48.5 ± 16 years) and individuals without a history of 
mental illness (n=19, mean age 55 ± 15.3 years) found smaller grey matter (GM) volume in the 
frontal but not other cerebral lobes in schizophrenia [12]. 
Longitudinal studies have reported frontal lobe volume reduction in patients with 
schizophrenia [13-15]. Studies have also examined the cross-sectional relationship between 
the duration of illness and frontal lobe volume [16-18]. Molina and colleagues [18] observed a 
loss of GM in the PFC in chronic (n = 29), but not first-episode (n = 22), schizophrenia patients 
and an association between cerebro-spinal fluid (CSF) excess in the PFC and duration of illness 
in male, but not female, patients [19]. Smaller PFC GM volume has been reported to be 
associated non-linearly with a longer duration of illness in chronic (n = 49) and first-episode (n = 
34) patients [16]. Less GM in the superior part of the dorsolateral PFC (DLPFC) has been 
associated with a longer duration of illness in chronic (n=21), but not first-episode (n = 22), 
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patients [20]. Longer duration of illness has also been associated with reduced GM in left 
temporal lobe and right posterior region, but not frontal lobe in neuroleptic-nai've first-episode 
patients (n = 14) [21]. More recently, another study [17] observed an inverse association 
between duration of illness and prefrontal cortical volume in stable outpatients (n = 28). A lower 
N-acetyl aspartate/Creatine ratio in the DLPFC is also associated with a longer duration of 
illness among schizophrenia patients (n = 35) [22]. A loss of PFC GM and NAA thus seems to 
be associated with a longer duration of illness, perhaps more reliably in the chronic than early 
course, in schizophrenia. 
Studying GM volume using voxel-based morphometry (VBM) can help detect the 
localized effects of duration of illness in schizophrenia patients. GM volume decrease in frontal 
and temporal regions over a five-year period has been observed, with a progressive GM loss in 
the left frontal lobe as the number of psychotic episodes increased [23]. One study [24] of 20 
schizophrenia patients (mean age = 37 years, median duration of illness = 15 years [2-41 
years]) did not observe any association between duration of illness and GM volume across the 
brain. Another study [25] (n = 39) reported (mean age = 36 years, median duration of illness = 
11 years [2-31 years]) an inverse association between duration of illness and GM volume in the 
medial temporal lobe, cerebellum and the anterior cingulate gyrus, but not in the frontal lobe. 
GM volume in the frontal and temporal lobes, as determined by ROI [26,27] and more recently 
by VBM [28,29] approaches, has also been found to change with age in healthy individuals. 
In this study, we examined the inverse association between duration of illness and GM 
volume as determined by VBM in a larger sample of patients with schizophrenia (n = 64) than 
previous studies that examined this association. We hypothesized that a longer duration of 
illness would be related to lower GM volume in the PFC. We, however, examined the 
relationship between the duration of illness and GM and CSF volumes across the whole brain to 
determine the specificity of a duration of illness-PFC volume association (if found). In order to 
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understand the cognitive and clinical factors associated with duration of illness, we also 
examined the association of duration of illness to executive function, memory, attention and 
motor dexterity and positive and negative symptoms and generalized psychopathology. Based 
on previous findings [30-32], we hypothesized that a longer duration of illness would be 
associated most strongly with poorer PFC-based cognitive function. 
2 Methods and Materials 
2.1 Participants and design 
Participants included 64 outpatients with a DSM-IV diagnosis of schizophrenia or 
schizoaffective disorder who were recruited as part of a longitudinal study on the effect of 
cognitive behavioural therapy (CBT) on the brain and 25 healthy controls. The present 
investigation utilized patients' data collected at baseline (prior to CBT). Patients were recruited 
from the South London and Maudsley NHS Trust and were on stable doses of antipsychotic 
medication for at least three months prior to taking part. Healthy participants were recruited 
from the local community and screened for personal history of mental illness using the SCID -
non-patient version [33]. No participant had a history of neurological or systemic illness or head 
injury. The study procedures and the use of data for the purpose of the current investigation 
were approved by the ethics committee of the joint research ethics committee of the South 
London and Maudsley NHS Foundation Trust and the Institute of Psychiatry, London. All 
participants provided written informed consent to their participation and were compensated for 
their time and travel. 
All participants underwent magnetic resonance imaging and were tested on a battery of 
neuropsychological tests. 
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2.2 Clinical assessments 
Clinical diagnostic interviews using the Structured Clinical Interview for DSM-IV (SCID) 
[34], and Positive and Negative Syndrome Scale (PANSS) assessments [35] were performed by 
an experienced consultant psychiatrist (DF). Duration of illness was defined as the difference 
between the age at onset of psychotic symptoms (as reported by the patient and where possible 
confirmed with other sources) and age at the time of scanning. 
2.3 Neuropsychological measures 
Participants were assessed on general intelligence and measures of executive function, 
memory, attention and motor dexterity (see Table 1). 
Insert Table 1 about here 
2.4 MR I acquisition 
Structural MRI brain scans were acquired using a 1.5 Tesla GE NV/I Signa system 
(General Electric, Milwaukee Wl, USA) at the Maudsley Hospital, London. Initially, a series of 
sagittal fast gradient echo scout images were acquired. A 3-D inversion recovery prepared fast 
spoiled GRASS sequence was applied to the whole brain to obtain T1-weighted images in the 
axial plane with 1.5mm contiguous sections (TR =18 ms, Tl = 450 ms, TE = 5.1 ms, flip angle = 
20 degrees with one data average and a 256 x 256 x 128 voxel matrix). 
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2.4.1 MRI pre-processing 
Structural images were converted into ANALYZE format (ANALYZE software, BRU, 
Mayo Foundation, Rochester, MN) and pre-processed using Statistical Parametric Mapping -
version 2 (SPM2, Wellcome Department of Imaging Neuroscience, London; 
http://www.fil.ion.ucl.ac.uk/spm), running in MATLAB 6.1 (MathWorks, Natick, MA). All images 
were manually realigned (three translations: right, forward and up; and three rotations: pitch, roll 
and yaw) to the anterior commissure-posterior commissure (AC-PC) line and the inter-
hemispheric fissure. 
2.4.2 Customised template creation 
Customised T1 -weighted templates of the whole brain, GM, WM and cerebro-spinal fluid 
(CSF) were created for patients and controls separately. For the creation of the customised 
whole brain (T1 -weighted) template, the images were spatially normalized to the standard 
SPM2 T1 -weighted template using a 12-parameter affine transformation. These normalised 
images were then smoothed with an 8mm full width at half maximum (FWHM) isotropic 
Gaussian kernel, and averaged to create a customised T1 -weighted template. The normalised 
T1 -weighted images were then segmented into their GM, WM and CSF components using the 
GM, WM and CSF probability maps inherent to SPM2. The resultant tissue segments were 
automatically cleaned to remove non-brain tissue and smoothed with an 8mm FWHM isotropic 
Gaussian kernel, normalized using affine transformation with sine interpolation algorithm and 
averaged to derive GM, WM and CSF probability maps. To reduce the partial volume problem 
and ensure optimal tissue segmentation, all images for the templates were written out with 
1x1x1 mm voxel size. 
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2.4.3 Deriving and applying optimized normalization parameters 
The structural scans were processed using the customized whole brain and tissue 
probability templates. The first step entailed a segmentation of the original images in native 
space, registering to the customized tissue probability map and correcting for image 
inhomogeneity, followed by an automatic brain extraction and cleaning procedure to remove 
non-brain tissue. The second step involved spatial normalization of the original images to the 
customized whole brain template using 12-parameter linear and 7x8x7 discrete cosine 
transform basis function non-linear transformation [36], with parameters determined from the 
images derived from the first step, and resliced to 1x1x1 mm voxel size to yield more accurate 
subsequent tissue segmentation. The spatially normalized images were then segmented into 
the three tissue compartments using the customized GM, WM and CSF templates. Brain 
extraction and cleaning procedures were re-applied to the segmented normalized GM images to 
further remove extraneous brain tissue. Since the volume of some brain regions may shrink or 
expand as a result of non-linear spatial normalization, the cleaned GM images were modulated, 
i.e., the voxel values of each segment were multiplied by the Jacobian determinants of the 
deformation matrix derived during the spatial normalization step to 'restore' the original volume 
of each GM segment. Finally, the GM and WM segments were smoothed using a 12-mm 
FWHM isotropic Gaussian kernel to make the data conform to the Gaussian field model, 
underlying the structural inferences as implemented in SPM2 to render the data more normally 
distributed (by the central limit theorem) and to reduce the effects of individual variation in 
sulcal/gyral anatomy [37]. 
2.5 Statistical analysis 
2.5.1 Group comparison on demographic characteristics 
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Group differences in demographic characteristics were examined with analysis of 
variance (ANOVA) and Chi-square tests. 
2.5.2 Group comparison on neuropsychological performance 
Differences between patients and controls in neuropsychological performance with age 
and years in education as covariates (because these variables differentiated the study groups; 
see Table 1) were examined by means of one-way analyses of covariance (ANCOVAs). 
2.5.3 Neuropsychological and clinical correlates of duration of illness 
The associations between duration of illness and (a) neuropsychological ability and (b) 
total PANSS and PANSS total positive, negative and general psychopathology subscale scores 
were determined with Pearson's correlations. Given that we expected only small-to-modest 
associations between duration of illness and poor cognitive function and the exploratory nature 
of the analysis concerning the relationship between duration of illness and symptoms, the 
significance level was set at p=0.05 and not corrected for multiple correlations. 
2.5.4 MRI analysis 
2.5.5 Effect of diagnosis on GM and CSF volume 
Reduction in GM volume and increase in CSF were explored across the whole brain in 
patients compared to controls by means of ANCOVAs at each voxel using SPM2 with diagnosis 
as a between-group factor, and age as a confounding covariate. The group difference map in 
GM volume across the whole brain was examined at an uncorrected height threshold p level < 
0.001; the differences which survived family-wise error correction at p level<0.05 were 
considered significant. 
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2.5.6 Association of GM or CSF volume with duration of illness and age in patients 
and with age in healthy controls 
The association between GM or CSF volume and duration of illness in patients was 
examined by means of multiple regressions between GM or CSF maps and duration of illness at 
each voxel. 
In order to disentangle the effects of age and duration of illness, we performed multiple 
regression analyses in patients with GM or CSF volume at each voxel of the regions where GM 
or CSF volumes were associated with duration of illness as the dependent variable and age and 
duration of illness as the predictor variables in order to determine which was the stronger 
predictor and the variance predicted by the two variables. 
We examined separately the association between age and GM or CSF volume in 
controls at the maxima voxels of all the regions where GM or CSF volumes were associated 
with duration of illness in patients by means of correlations between the values representing the 
percentage of total grey/white matter volume under a smoothing kernel relative to the total 
grey/white matter volume extracted for each participant and age at each voxel. 
We further examined the GM volume association with duration of illness in patients with 
a schizophrenia diagnosis only (n = 56). 
2.5.7 GM volume, duration of illness and neuropsychological performance in 
patients 
We extracted the values representing the percentage of total grey/white matter volume 
under a smoothing kernel relative to the total grey/white matter volume for each participant in 
the patient group at the maxima voxels of all the regions where GM volumes were associated 
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with duration of illness in patients. We performed Pearson correlations between these values 
and performance scores on the neuropsychological measures. 
3 Results 
Patients had a fewer number of years in education (see Table 2). Fifty-three patients 
were receiving atypical (clozapine=10, risperidone=10, olanzapine=22, quetiapine=2, 
amisulperide=2, aripiprazole=2), eleven were receiving typical (chlorpromazine=1, 
flupenthixol=3, sulperide=3, haloperidol=2, fluphenazine=1, thioridazine^) and three were 
receiving both atypical and typical antipsychotics. 
Insert Table 2 about here 
3.1 Effect of diagnosis on neuropsychological performance 
Patients had lower IQ and performed poorly relative to healthy controls on most 
neuropsychological measures (see Table 3). 
Insert Table 3 about here 
3.2 Neuropsychological and clinical correlates of duration of illness 
Duration of illness did not correlate with any neuropsychological measure; the strongest 
but still non-significant correlation was with general intelligence (r=-0.17, p=0.19). 
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Duration of illness was not significantly associated with current positive symptoms (r=-
0.02, p=0.87), negative symptoms (r=0.02, p=0.91), general psychopathology (r=-0.06, p=0.64) 
or total PANSS scores (r=-0.06, p=0.64). 
3.3 Effect of diagnosis on GM and CSF volume across the whole brain 
Patients had lower GM volume in the left and right dorsolateral PFC, left and right middle 
temporal gyrus and left anterior cingulate gyrus (see Table 4 and Figure 1). The GM reduction 
was greatest in the left dorsolateral PFC. A CSF excess in patients was present near the 
superior frontal gyrus bilaterally, right dorsolateral PFC, left superior temporal gyri and right 
precentral gyrus. 
Insert Table 4 and Figure 1 about here 
3.4 GM correlates of duration of illness in patients and age in healthy 
controls 
A longer duration of illness was associated with lower GM volume in the left dorsomedial 
PFC, right middle frontal cortex, left fusiform gyrus (FG) and left cerebellum (see Table 5 and 
Figure 2) and with a CSF excess near the left cerebellum. Among patients with a schizophrenia 
diagnosis only, a longer duration of illness was associated with lower GM volume in the left 
dorsomedial PFC and right middle frontal cortex and a CSF excess near the left inferior frontal 
gyrus. 
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Duration of illness predicted 19.6% of the variance in GM volume of the left dorsomedial 
PFC (r=-0.44, p<0.001), while age predicted a further 6% of the variance (partial r=-0.32, 
p=0.04, overall F=10.3, df=63,2, p<0.001). 
Duration of illness predicted 16.7% of the variance in GM volume of the right middle 
frontal cortex (r=-0.41, p=0.001), while age predicted a further 0.01% (negligible) of the variance 
(partial r=0.04, p=0.78, overall F=6.15, df=63,2, p=0.004). 
Duration of illness predicted 16.8% of the variance in GM volume of the left fusiform 
gyrus (r=-0.41, p=0.001), while age predicted a further 0.03% of the variance (partial r=-0.08, 
p=0.61, overall F=6.29, df=63,2, p=0.003). 
Duration of illness predicted 16% of the variance in GM volume of the left cerebellum 
(lobule III) (r=-0.4, p=0.001), while age predicted a further 2% of the variance (partial r=0.2, 
p=0.2, overall F=6.77, df=63,2, p=0.002). 
In healthy controls, age was associated with GM volume in the left FG (r=-0.39, p=0.05) 
and with CSF volume near the cerebellum (r=0.48, p=0.02) and at a trend level with GM volume 
in the left dorsomedial PFC (partial r=-0.37, p=0.07). 
Insert Table 5 and Figure 2 about here 
3.5 GM volume, duration of illness and neuropsychological 
performance in patients 
Greater GM volume in the dorsomedial PFC was associated with better performance on 
the letter-number test (r=0.3, p=0.02), Stroop Interference (r=0.38, p=0.002) and shorter time to 
completion on the Groove pegboard dominant task (r=-0.25, p=0.04). 
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4 Discussion 
We aimed to determine whether a longer duration of illness is related to GM loss and 
CSF excess in the PFC in patients with schizophrenia. Our study found that longer duration of 
illness was associated with lower GM volume in the left dorsomedial prefrontal and right middle 
frontal cortices, left FG and left cerebellum (lobule III) in patients with schizophrenia or 
schizoaffective disorder. GM volume in the left dorsomedial PFC was influenced by age in 
addition to the duration of illness. In schizophrenia patients only, duration of illness was 
associated with lower GM volume in the left dorsomedial prefrontal and right middle frontal 
cortices and with CSF excess near the left inferior frontal gyrus. In controls, age was inversely 
associated with GM volume in the left FG and CSF excess near the cerebellum, and at a trend 
level with GM volume in the left dorsomedial PFC. Compared to controls, patients had lower 
GM volume bilaterally in the DLPFC and middle temporal gyrus and left anterior cingulate gyrus 
and a CSF excess in areas close to the superior frontal gyrus bilaterally, right dorso-lateral PFC, 
left superior temporal gyrus and right precentral gyrus. Greater GM volume in the left 
dorsomedial PFC was associated with better working memory, attention and psychomotor 
speed in patients. 
The relationships between longer duration of illness and lower GM volume in the left 
dorsomedial prefrontal and middle frontal cortices in patients with schizophrenia or 
schizoaffective disorder and CSF excess near the inferior frontal gyrus in patients with 
schizophrenia support the hypothesis that the frontal lobe may be vulnerable to the long-term 
effects of schizophrenia-related morbidity and findings from previous ROI studies [16,18]. The 
extended maturation period of the frontal lobe of up to 47 years [6] may create a larger window 
of vulnerability to abnormal neurodevelopment of selected areas of the frontal lobe among some 
schizophrenia patients. Our findings may simply reflect neurodegeneration with normal ageing, 
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though normal ageing and duration of illness may be closely related and it may be difficult to 
separate the two effects. Age, in addition to duration of illness, was a significant predictor of 
GM volume in the dorsomedial PFC, suggesting that both factors may influence GM volume in 
the dorsomedial PFC in schizophrenia patients. The association between GM volume in the 
right middle frontal cortex and duration of illness was not influenced by age and GM volume in 
this region was not associated with age in controls, suggesting that this part of the frontal lobe 
may show more illness-specific effects than the PFC. 
There was no direct association between duration of illness and neuropsychological 
function or symptom severity. However, greater GM volume in the left dorsomedial PFC was 
associated with better neuropsychological performance on measures that reflect frontal lobe 
functioning in patients. This would suggest that duration of illness effects are seen at the neural 
level, or are less sensitive to impairment at the neuropsychological and clinical levels of 
analysis. Duration of illness may not directly influence neuropsychological function, but the 
associated GM deficit in the left dorsomedial PFC may indirectly have a negative effect on 
frontal lobe-based neuropsychological function and is consistent with the evidence for the 
presence of such structure-function relationships in chronic patients [38-40]. A longer duration 
of illness may have a deleterious effect on frontal lobe-based structure-function relationships. 
The association between longer duration of illness and lower GM volume and CSF 
excess in the cerebellum is consistent with an earlier report of an association between longer 
duration of illness and cerebellar GM volume using VBM in chronic patients [25], though it was 
not observed using the ROI approach in our previous study [16]. It is possible that the duration 
of illness effect may be localised to specific regions within the cerebellum. Deficits may be 
localized to certain areas that are related to cognitive function [41-43] and functional outcome 
[44]. Cerebellum has been traditionally considered in terms of its role in balance and motor co-
ordination. Recent functional imaging, cerebellar lesion, animal studies and experimental 
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studies in people with schizophrenia have widened its field of reference to other cognitive 
functions, in particular procedural learning and working memory [45-48]. The long-term effects 
of schizophrenia on the cerebellum may in part contribute to the observed cognitive deficits in 
the patients. Age was associated with a CSF excess near this region in controls, suggesting 
that normal ageing may also be associated with changes in this region. 
We also observed an association between longer duration of illness and lower GM 
volume in the left FG in patients and between age and lower GM volume in the left FG in 
controls. Age-related decline in brain activation in the FG during cognitive performance has 
been observed [49,50], suggesting that age-related decline may take place in the FG. 
There was no overlap between localised areas showing an association between duration 
of illness and GM volume and those areas showing reduced GM volume or a CSF excess 
relative to healthy controls. This may be because significant group differences would be evident 
only in those regions that show lower GM volume in the majority of the patient sample. 
Our study has some limitations. This was a retrospective study. The duration of illness 
construct is a proxy for the long-term effects of illness chronicity and may subsume more than 
just the long-term experience of schizophrenia. It may reflect longer contact with clinical 
services. Furthermore, the analyses of the association between duration of illness and 
neuropsychological function, clinical symptoms and GM volume were correlational in nature and 
thus do not inform about the direction of causality. We did not have reliable information to be 
able to examine the potential influence on GM volume of the duration of the period prodromal to 
the first frank illness episode, nor for the total length of medication in the observed brain-
duration of illness relationships; the age of onset of psychotic symptoms and age at first 
hospitalization/onset of antipsychotic medication, as reported by the patients, were very close in 
time in our sample. Finally, we did not control for alcohol, tobacco and illegal drug consumption 
that are known to influence cortical volumes [51,52]. 
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In conclusion, the right middle frontal cortex may be vulnerable to the long-term effect of 
schizophrenia illness whereas both a long duration of illness and advance age influence the 
dorsomedial PFC, FG and cerebellum. The effect of illness chronicity on GM volume in the left 
dorsomedial PFC may be extended to frontal lobe brain structure-neuropsychological function 
relationships. The effect of illness chronicity on GM volume in the left dorsomedial PFC may be 
extended to brain structure-neuropsychological function relationships. 
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Table 1: Table of neuropsychological measures 
General intelligence 
Wechsler Abbreviated Scale of Intelligence (WASI) Vocabulary and Matrix Design [53] 
Executive function 
Wisconsin Card Sorting Test [54] 
Hayling Test [55] 
Verbal fluency [56] 
Working Memory 
Letter-Number Test [57] 
Short-term/long-term memory 
WMS-R Logical Memory [58] 
Hopkins Verbal Learning Test (HVLT) [59] 
Attention 
Continuous Performance Test - Identical Pairs [60] 
StroopTest[61] 
Psychomotor speed 
Grooved Pegboard Test [62] 
23 
P
-Print
Table 2: Demographic and clinical characteristics of patients and healthy controls 
Characteristic 
Age - mean, s.d., range 
Sex (male/female) 
Handedness (right-handed/ 
ambidexterous) 
Years in education - mean, s.d., 
range 
Diagnosis 
Schizophrenia 
Paranoid 
Residual 
Undifferentiated 
Schizoaffective 
Duration of illness - mean, s.d. 
Age at illness onset - mean, s.d., 
range 
Symptoms (PANSS) - mean, s.d., 
range 
Positive 
Negative 
Generalised psychopathology 
Total 
Patient 
(n = 64) 
38.6,9.6, 19-61 
48/16 
62,2 
13.8,2.6,8-20 
48 
4 
4 
8 
13.7,9.7, 1-43 
24.9,8.0, 10-50 
16.1,4.8,7-25 
17.7,5.0,7-28 
32.3,6.7, 18-56 
66.2, 13.9,37-108 
Control 
(n = 25) 
36.4, 11.1,25-65 
15/10 
31,2 
15.2,2.6, 10-20 
ANOVA/x2 p 
+0.83 
*1.96 
*2.29 
+4.63 
0 
0 
+t statistic; *Chi-square statistic 
24 
Pre-Print
Table 3: Comparison of neuropsychological performance between patients and controls 
controlling for age and years in education. 
Neuropsychological measure 
Patient Control ANOVA Effect 
size 
n mean (s.d.) n mean (s.d.) F p (partial 
eta2) 
General intelligence 
WASI IQ 
Executive function 
WCST perseverative errors 
Hayling Btime 
Verbal fluency - letters 
Verbal fluency - categories 
63 
64 
61 
64 
64 
103.3(20.1) 
24.5(17.6) 
36.9 (36.2) 
36.1 (13.1) 
39.4(11.2) 
25 
22 
24 
23 
23 
Working memory 
Letter-number 
Short-term memory 
HVLT total recalled 
Logical memory immediate recall 
Long-term memory 
Logical memory delayed recall 
Sustained Attention 
Continuous Performance Test -
discriminability 
Stroop Interference 
Motor dexterity 
Grooved pegboard - dominant 
Grooved pegboard - non-dominant 
11.9(9.5) 10.17 0.002 0.11 
26.9(39.8) 1.25 0.3 0.02 
48(17.5) 11.52 0.001 0.12 
53(15.1) 20.56 <0.001 0.2 
64 13.0(4.2) 22 9.9(3.2) 11.55 0.001 0.12 
63 20.6(5.8) 22 27.3(4.5) 24.7 <0.001 0.23 
63 6.6(3.1) 22 9.8(3.2) 18.33 <0.001 0.18 
63 7.6(2.5) 22 10.5(3.2) 18.33 <0.001 0.18 
62 0.9(0.6) 21 1.5(0.8) 15.44 <0.001 0.16 
62 0.02(9.3) 21 3.1(15.3) 1.2 0.3 0.02 
63 94.4(63.7) 24 62.4(14) 5.9 0.02 0.07 
63 113.4(86.3) 24 76.3(20) 4.3 0.04 0.05 
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Table 4. Brain areas showing G M reduction and CSF excess in patients relative to healthy 
controls correcting for age (height threshold p = 0.001, cluster size>25 voxels) 
Jrain Region 
G M reduction 
Dorsolateral P F C 
Dorsolateral P F C 
Anterior cingulate gyrus 
Middle temporal gyrus 
Middle temporal gyrus 
C S F excess adjacent to 
Dorsolateral P F C 
Superior frontal gyrus 
Superior temporal gyrus 
Superior frontal gyrus 
Precentral gyrus 
Superior frontal gyrus 
Left/ 
right 
R 
L 
L 
L 
R 
R 
R 
L 
R 
R 
L 
Brodmann 
Area L/R 
46 
46 
24 
21 
40 
MNI 
Coordinates 
x y z 
38 
-33 
1 
-52 
48 
51 
22 
-57 
6 
24 
-7 
41 
41 
-12 
-41 
-47 
34 
28 
18 
12 
8 
-1 
27 
19 
39 
2 
24 
-17 
55 
-25 
58 
83 
66 
t 
value 
4.99 
3.75 
4.09 
4.03 
4.37 
5.29 
4.27 
3.88 
4.01 
3.38 
3.52 
Number of 
contiguous 
voxels 
2715 
390 
2613 
943 
755 
2282 
509 
512 
1056 
80 
34 
Family-
wise error 
corrected 
p-value 
<0.001 
0.004 
0.002 
0.002 
0.001 
<0.001 
0.001 
0.004 
0.003 
0.019 
0.012 
Voxel 
equiv 
Z 
4.66 
3.6 
3.9 
3.84 
4.14 
4.91 
4.05 
3.71 
3.83 
3.26 
3.39 
P F C : Prefrontal cortex; MNI: Montreal Neurological Institute. 
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Table 5: Brain areas showing an association between duration of illness and GM volume and 
CSF in patients with schizophrenia or schizoaffective disorder (height threshold p < 0.001, 
cluster size >25 voxels) 
Brain Region Left/ Brodmann 
right Area L/R 
MNI 
Coordinates 
x y 
Patients 
Inverse association between duration of illness and GM 
Dorsomedial PFC L 8 -2 
Middle frontal cortex R 6/8 35 
Fusiform gyrus L 37 -41 
Cerebellum (lobule III) L -52 
t Number of 
voxels 
49 
7 
•37 
•46 
45 
49 
-18 
-30 
3.89 
3.52 
3.53 
3.43 
186 
96 
98 
134 
Family-
wise error 
corrected 
p-value 
0.004 
0.01 
0.01 
0.013 
Equiv 
Z 
3.66 
3.35 
3.36 
3.27 
Positive association between duration of illness and CSF excess adjacent to 
Cerebellum L -11 -28 -15 4.20 492 0.002 3.92 
Inverse association between duration of illness and GM in patients with a schizophrenia diagnosis only (n = 56) 
Dorsomedial PFC L 8 -17 46 41 4.36 1178 0.001 4.02 
Middle frontal cortex R 6 35 7 49 4.05 387 0.003 3.77 
Positive association between duration of illness and CSF excess in patients with a schizophrenia diagnosis only (n 
= 56) 
Inferior frontal gyrus L 28 -19 7 -21 3.99 327 0.005 3.72 
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Figure 1: Areas showing reduced GM in patients relative to healthy controls (height threshold p = 0.001) 
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Figure 2: Inverse associations between duration of illness and GM volume in patients (height threshold p = 0.002) 
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